Insider buying last 90 days
No open-market insider purchases were filed for BIO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BIO insider filing, plotted on the chart in Gekko.Open BIO in Gekko
NYSE: BIO
Bio-Rad Laboratories (BIO) Stock Analysis & Forecast
Sep 28 close
$377.69−3.31 (−0.9%)
Gekko Brief
AI summaryBio-Rad Laboratories draws attention this week on a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective approach to acquisitions. The company also presented at the Bernstein Insights Healthcare Leaders and Disruptors forum, and commentary points to Clinical Diagnostics strength and international reach supporting growth, while China weakness, geopolitics and FX are flagged as risks to watch.
BIO closed at $377.69, down 0.9%, sitting above both its 50-day average of $360.52 and 200-day average of $306.54, with the 50-day above the 200-day. The GekkoIndex reads 54.3, placing it in the Neutral zone, up 0.9 over five sessions. Price sits 8.6% above the Gekko Fair Value of $347.81.
The next earnings report falls on 4 November 2026, after the close, 36 days out and beyond a typical 20-trading-day holding window. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows, and there are zero billionaire holders against one trailblazer holder on record. Seasonality from this point in the calendar has averaged -1.9% over the next 20 trading days across 5 years, rising in 2 of them. Analyst coverage shows 1 buy and 2 hold ratings among 3 firms, with a consensus target of $328.75.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Bio-Rad Laboratories price vs fair value
Close $377.69200-day averageGekko Fair Value $347.81
Bio-Rad Laboratories quick facts
- Market cap
- $10.17B
- P/E ratio
- 46.5
- Forward P/E
- 41.3
- EPS, TTM
- $8.19
- Revenue, TTM
- $2.59B
- Profit margin
- 8.6%
- Dividend yield
- —
- Beta
- 1.07
- Volume
- 258,670 avg 271,693
- 1-year return
- +39.7%
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±5.7%
- 50-day average
- $360.52
- 200-day average
- $306.54
- Next earnings
- Nov 4 after close
- Shares outstanding
- 21.68M
Bio-Rad Laboratories swing-trade checklist
Bio-Rad Laboratories scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $377.69 is above the 50-day ($360.52) and 200-day ($306.54) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
54.3, Neutral
Reading 54.3 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
8.6% above
Price is 8.6% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−1.9% on average
From this point in the calendar, the next 20 trading days averaged −1.9% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Bio-Rad Laboratories stock chart and price history
Bio-Rad Laboratories closed at $377.69 on Sep 28, 2026, +39.7% over the past year, inside a 52-week range of $236.73 to $396.23.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −3.1%
- 3 months
- +27.9%
- 6 months
- +42.3%
- 1 year
- +39.7%
The full BIO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BIO in Gekko
Follow Bio-Rad Laboratories through every session
Put BIO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BIO in GekkoFree for 7 days. No credit card required.
About Bio-Rad Laboratories
Bio-Rad Laboratories makes and sells equipment, reagents, and testing systems used in life science research and clinical diagnostics. Its work includes tools for separating and analyzing chemical and biological materials, and it is known for supplying laboratories with both instruments and the diagnostic kits that go with them. Customers reach the company across the United States, Canada, Europe, Asia, and Latin America.
The business runs through two divisions. The Life Science division builds reagents, instruments, and lab equipment for work in proteomics, genomics, biopharmaceutical manufacturing, cellular biology, and food safety, selling to universities, medical schools, government and industrial research bodies, pharmaceutical and biotech firms, and food producers and testing labs. The Clinical Diagnostics division supplies test systems, diagnostic kits, informatics tools, and quality control products for niche areas of in vitro diagnostics, serving reference and hospital laboratories, newborn screening centers, physicians' offices, and transfusion labs. Products reach customers through a direct sales force alongside distributors, agents, brokers, and resellers.
Bio-Rad Laboratories was founded in 1952 and is based in Hercules, California. Its shares are listed on the NYSE under the ticker BIO.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- bio-rad.com
Bio-Rad Laboratories GekkoIndex: the smart money zone
Bio-Rad Laboratories’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.3, in the Neutral zone, up 0.9 points over five sessions.
54.3Neutral
Up 0.9 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 41 | −1.0% | −0.6% | ||
| Accumulation | 193 | +1.1% | +2.8% | ||
| Neutral (current zone) | 392 | +0.2% | +0.3% | ||
| Distribution | 44 | −1.2% | +0.2% | ||
| Selling | 2 | Too few readings yet | |||
Average BIO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BIO price, zone by zone.Track BIO in Gekko
Is Bio-Rad Laboratories stock overvalued? Gekko Fair Value
Bio-Rad Laboratories trades 8.6% above Gekko Fair Value of $347.81, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Bio-Rad Laboratories shares are worth, recalculated every trading day.
$347.81
Gekko Fair Value, Sep 29, 2026
8.6% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BIO in Gekko
Bio-Rad Laboratories insider and Congress trading
No open-market insider purchases were filed for Bio-Rad Laboratories, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BIO were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BIO, plotted on the chart in Gekko.Open BIO in Gekko
Buybacks
Bio-Rad Laboratories has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $31.50M
- As a share of market cap
- 0.31%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds BIO.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Bio-Rad Laboratories earnings: next date and track record
Bio-Rad Laboratories reports on Nov 4, 2026, after the close (36 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 36 days away
- EPS estimate
- $2.23
- Revenue estimate
- $650.6M
7 of 8reports beat the EPS estimate
±6.8%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 12, 2026 AI summary
- What they said
- Bio-Rad delivered 2025 results within revised guidance for revenue and operating margin, but gross margin underperformed due to supply chain execution issues. Diagnostics returned to growth driven by quality control orders and China diabetes testing normalization. Life Science saw strong QX700 Digital PCR instrument adoption with meaningful Q4 acceleration, while process chromatography grew over 20% for the year.
- Guidance
- Management expects modest recovery in Life Science from biopharma markets in 2026. Planned product launches include IVD version of QX600 and additional high-value ddPCR assays across oncology.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 12, 2026 | $2.51 est $2.57 | $693.2M est $688.8M | −12.6% |
| Oct 30, 2025 | $2.26 est $1.94 | $653.0M est $694.6M | 0.0% |
| Jul 31, 2025 | $2.61 est $1.93 | $651.6M est $633.8M | +13.8% |
| May 1, 2025 | $2.54 est $1.73 | $585.4M est $573.2M | −3.2% |
| Feb 13, 2025 | $2.90 est $2.88 | $667.5M est $679.8M | −11.3% |
| Oct 30, 2024 | $2.01 est $1.18 | $649.7M est $681.3M | +8.0% |
| Aug 1, 2024 | $3.11 est $2.01 | $638.5M est $645.8M | −0.7% |
| May 7, 2024 | $2.29 est $2.15 | $610.8M est $619.1M | −4.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Bio-Rad Laboratories stock forecast and analyst price targets
Analysts’ average 12-month price target for Bio-Rad Laboratories is $328.75, −13.0% from the last close, from 3 firms rating the stock in the last 90 days.
$328.75consensus 12-month target, −13.0% from the last close
Now $377.69Avg $328.75
Low $330High $390
Each firm’s latest rating in the last 90 days: 3 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 27 | RBC Capital | $390 | +3.3% |
| Aug 5 | Wells Fargo | $330 | −12.6% |
| Aug 5 | Citi | $330 | −12.6% |
| Aug 4 | RBC Capital | $370 | −2.0% |
+0.3%average 20-day move after past Neutral readings
−1.9%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Bio-Rad Laboratories seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Bio-Rad Laboratories averaged −1.9% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.5% | 3 of 5 |
| Next 10 trading days | −0.2% | 2 of 5 |
| Next 15 trading days | 0.0% | 2 of 5 |
| Next 20 trading days | −1.9% | 2 of 5 |
| Next 30 trading days | +2.0% | 3 of 5 |
For scale, BIO’s typical 20-trading-day move in either direction is about 5.7%.
Bio-Rad Laboratories market cap and key statistics
Bio-Rad Laboratories’s market cap is $10.17B, with a P/E ratio of 46.5 and revenue of $2.59B over the last twelve months.
Valuation
- Market cap
- $10.17B
- P/E ratio
- 46.5
- Forward P/E
- 41.3
- EPS, TTM
- $8.19
- Gekko Fair Value
- $347.81
Trading
- Volume
- 258,670
- Avg volume, 20 days
- 271,693
- 52-week high
- $396.23
- 52-week low
- $236.73
- Shares outstanding
- 21.68M
Financials
- Revenue, TTM
- $2.59B
- Profit margin
- 8.6%
- Return on equity
- 3.1%
- Quarterly earnings growth, YoY
- +18.7%
Risk and income
- Beta
- 1.07
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±5.7%
Bio-Rad Laboratories stock news this week
4 headlines about Bio-Rad Laboratories from the past week, newest first, each linking to the publisher.
- Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A GrowthMarketBeat, Sep 25
- Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum TranscriptSeeking Alpha, Sep 24
- Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for NowZacks Investment Research, Sep 23
- BIO-key Receives FIDO Alliance Full Certification for Passkey:YOU™ Authentication, Unlocking New Markets Including Agentic AI Authenticated ControlsGlobeNewsWire, Sep 23
Bio-Rad Laboratories peers
Bio-Rad Laboratories’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
Bio-Rad Laboratories stock FAQ
What is Bio-Rad Laboratories’s market cap?
Bio-Rad Laboratories’s market cap is $10.17B at the Sep 28, 2026 close of $377.69, with 21.68M shares outstanding. The shares trade on a P/E ratio of 46.5.
What is the Bio-Rad Laboratories stock forecast?
The consensus analyst 12-month price target for Bio-Rad Laboratories is $328.75, −13.0% from the last close. Of the 3 firms that rated the stock in the last 90 days, 1 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Bio-Rad Laboratories stock overvalued or undervalued?
On Gekko’s estimate Bio-Rad Laboratories is overvalued: the Sep 28, 2026 close of $377.69 is 8.6% above Gekko Fair Value of $347.81. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Bio-Rad Laboratories report earnings next?
Bio-Rad Laboratories is expected to report on Nov 4, 2026, after the market closes (36 days away). Analysts expect earnings of $2.23 per share on revenue of $650.6M. Bio-Rad Laboratories beat the earnings estimate in 7 of its last 8 reports, moving 6.8% on average across the report.
What is Bio-Rad Laboratories’s 52-week high and low?
Bio-Rad Laboratories’s 52-week high is $396.23 and its 52-week low is $236.73; it closed at $377.69 on Sep 28, 2026, +39.7% over the past year. Over the last five years the shares peaked at $798.97 on Oct 29, 2021.
Is Bio-Rad Laboratories stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Bio-Rad Laboratories the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.